Growth inhibitory activity of a novel lectin from Cliona varians against K562 human erythroleukemia cells
Purpose In this study, the antitumoral potential of a novel lectin (CvL) purified from the marine sponge Cliona varians was studied in different cancer cell lines. Methods CvL cytotoxicity was evaluated in mammalian tumor cells and in normal human peripheral blood lymphocytes by the MTT assay using...
Gespeichert in:
Veröffentlicht in: | Cancer chemotherapy and pharmacology 2009-05, Vol.63 (6), p.1023-1033 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1033 |
---|---|
container_issue | 6 |
container_start_page | 1023 |
container_title | Cancer chemotherapy and pharmacology |
container_volume | 63 |
creator | Queiroz, Alexandre F. S Silva, Rodrigo A Moura, Raniere M Dreyfuss, Juliana L Paredes-Gamero, Edgar J Souza, Ana C. S Tersariol, Ivarne L. S Santos, Elizeu A Nader, Helena B Justo, Giselle Z de Sales, Maurício P |
description | Purpose In this study, the antitumoral potential of a novel lectin (CvL) purified from the marine sponge Cliona varians was studied in different cancer cell lines. Methods CvL cytotoxicity was evaluated in mammalian tumor cells and in normal human peripheral blood lymphocytes by the MTT assay using the same range of concentrations (1-150 μg ml⁻¹). The mechanisms involved in K562 cell death were investigated by confocal fluorescence microscopy, flow cytometry and immunoblot. Results CvL inhibited the growth of human leukemia cells, with IC₅₀ values of 70 and 100 μg ml⁻¹ for K562 and JURKAT cells, respectively, but it was ineffective on blood lymphocytes and solid tumor cell lines. K562 cell death occurred 72 h after exposure to the lectin and with signs of apoptosis, as analyzed by DAPI and annexin V/PI staining. Investigation of the possible mediators of this process showed that cell death occurred via a caspase-independent pathway. Confocal fluorescence microscopy indicated a pivotal role for the lysosomal protease cathepsin B in mediating cell death. Accordingly, pre-incubation of K562 cells with the cathepsin inhibitor l-trans-epoxysuccinyl-l-leucylamido-(4-guanidino)butane (E-64) abolished CvL cytotoxic effect. Furthermore, we found upregulation of tumor necrosis factor receptor 1 (TNFR1) and down-modulation of p65 subunit of nuclear factor kappa B (NFκB) expression in CvL-treated cells. These effects were accompanied by increased levels of p21 and reduced expression of pRb, suggesting that CvL can induce cell cycle arrest. Conclusions Collectively, these findings indicate an antileukemic effect for CvL and suggest that cathepsin B acts as a death mediator in CvL-induced cytotoxicity possibly in an uncharacterized connection with the membrane death receptor pathway. |
doi_str_mv | 10.1007/s00280-008-0825-4 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20601452</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20601452</sourcerecordid><originalsourceid>FETCH-LOGICAL-c563t-54e72c28b1602e9a4c0664f1ef11009ff0a48bf7a1771b16ded25a9094592bad3</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS0EokvhA3ABCwluKTO28-9YraAgKvVQerYmWXvXJbGLnSzab1-vsqISB06WPb83bzyPsbcIFwhQf04AooECoCmgEWWhnrEVKinyTcnnbAVSqaKsQZ2xVyndA4BCKV-yM2zqBiWIFXNXMfyZdtz5nevcFOKBUz-5vZsOPFhO3Ie9Gfhg8qPnNoaRrwcXPPE9RUc-cdqS82niP8pK8N08kucmHqZdDIOZf5nREe_NMKTX7IWlIZk3p_Oc3X398nP9rbi-ufq-vrwu-rKSU1EqU4teNB1WIExLqoeqUhaNxfzn1log1XS2JqxrzNDGbERJLbSqbEVHG3nOPi19H2L4PZs06dGl4wTkTZiTFlABqlJk8MM_4H2Yo8-zaYFSNTIvKUO4QH0MKUVj9UN0I8WDRtDHEPQSgs4h6GMIWmXNu1PjuRvN5klx2noGPp4ASj0NNpLvXfrLZXesRF1nTixcyiW_NfFpwv-5v19EloKmbcyN724FZGOs8Lgk-QiGNKdu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213483878</pqid></control><display><type>article</type><title>Growth inhibitory activity of a novel lectin from Cliona varians against K562 human erythroleukemia cells</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Queiroz, Alexandre F. S ; Silva, Rodrigo A ; Moura, Raniere M ; Dreyfuss, Juliana L ; Paredes-Gamero, Edgar J ; Souza, Ana C. S ; Tersariol, Ivarne L. S ; Santos, Elizeu A ; Nader, Helena B ; Justo, Giselle Z ; de Sales, Maurício P</creator><creatorcontrib>Queiroz, Alexandre F. S ; Silva, Rodrigo A ; Moura, Raniere M ; Dreyfuss, Juliana L ; Paredes-Gamero, Edgar J ; Souza, Ana C. S ; Tersariol, Ivarne L. S ; Santos, Elizeu A ; Nader, Helena B ; Justo, Giselle Z ; de Sales, Maurício P</creatorcontrib><description>Purpose In this study, the antitumoral potential of a novel lectin (CvL) purified from the marine sponge Cliona varians was studied in different cancer cell lines. Methods CvL cytotoxicity was evaluated in mammalian tumor cells and in normal human peripheral blood lymphocytes by the MTT assay using the same range of concentrations (1-150 μg ml⁻¹). The mechanisms involved in K562 cell death were investigated by confocal fluorescence microscopy, flow cytometry and immunoblot. Results CvL inhibited the growth of human leukemia cells, with IC₅₀ values of 70 and 100 μg ml⁻¹ for K562 and JURKAT cells, respectively, but it was ineffective on blood lymphocytes and solid tumor cell lines. K562 cell death occurred 72 h after exposure to the lectin and with signs of apoptosis, as analyzed by DAPI and annexin V/PI staining. Investigation of the possible mediators of this process showed that cell death occurred via a caspase-independent pathway. Confocal fluorescence microscopy indicated a pivotal role for the lysosomal protease cathepsin B in mediating cell death. Accordingly, pre-incubation of K562 cells with the cathepsin inhibitor l-trans-epoxysuccinyl-l-leucylamido-(4-guanidino)butane (E-64) abolished CvL cytotoxic effect. Furthermore, we found upregulation of tumor necrosis factor receptor 1 (TNFR1) and down-modulation of p65 subunit of nuclear factor kappa B (NFκB) expression in CvL-treated cells. These effects were accompanied by increased levels of p21 and reduced expression of pRb, suggesting that CvL can induce cell cycle arrest. Conclusions Collectively, these findings indicate an antileukemic effect for CvL and suggest that cathepsin B acts as a death mediator in CvL-induced cytotoxicity possibly in an uncharacterized connection with the membrane death receptor pathway.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-008-0825-4</identifier><identifier>PMID: 18781302</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag</publisher><subject>Animals ; Antineoplastic agents ; Antineoplastic Agents - isolation & purification ; Antineoplastic Agents - pharmacology ; Apoptosis - drug effects ; Biological and medical sciences ; Cancer Research ; Caspases - metabolism ; Cell Culture Techniques ; Cell Proliferation - drug effects ; Cell Survival - drug effects ; Cliona ; Clione - chemistry ; Flow Cytometry ; Hematologic and hematopoietic diseases ; Humans ; Immunoblotting ; Inhibitory Concentration 50 ; Jurkat Cells ; K562 Cells ; Lectins - isolation & purification ; Lectins - pharmacology ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphocytes - cytology ; Lymphocytes - drug effects ; Medical sciences ; Medicine ; Medicine & Public Health ; Oncology ; Original Article ; Pharmacology. Drug treatments ; Pharmacology/Toxicology</subject><ispartof>Cancer chemotherapy and pharmacology, 2009-05, Vol.63 (6), p.1023-1033</ispartof><rights>Springer-Verlag 2008</rights><rights>2009 INIST-CNRS</rights><rights>Springer-Verlag 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c563t-54e72c28b1602e9a4c0664f1ef11009ff0a48bf7a1771b16ded25a9094592bad3</citedby><cites>FETCH-LOGICAL-c563t-54e72c28b1602e9a4c0664f1ef11009ff0a48bf7a1771b16ded25a9094592bad3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00280-008-0825-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00280-008-0825-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21316277$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18781302$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Queiroz, Alexandre F. S</creatorcontrib><creatorcontrib>Silva, Rodrigo A</creatorcontrib><creatorcontrib>Moura, Raniere M</creatorcontrib><creatorcontrib>Dreyfuss, Juliana L</creatorcontrib><creatorcontrib>Paredes-Gamero, Edgar J</creatorcontrib><creatorcontrib>Souza, Ana C. S</creatorcontrib><creatorcontrib>Tersariol, Ivarne L. S</creatorcontrib><creatorcontrib>Santos, Elizeu A</creatorcontrib><creatorcontrib>Nader, Helena B</creatorcontrib><creatorcontrib>Justo, Giselle Z</creatorcontrib><creatorcontrib>de Sales, Maurício P</creatorcontrib><title>Growth inhibitory activity of a novel lectin from Cliona varians against K562 human erythroleukemia cells</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><addtitle>Cancer Chemother Pharmacol</addtitle><description>Purpose In this study, the antitumoral potential of a novel lectin (CvL) purified from the marine sponge Cliona varians was studied in different cancer cell lines. Methods CvL cytotoxicity was evaluated in mammalian tumor cells and in normal human peripheral blood lymphocytes by the MTT assay using the same range of concentrations (1-150 μg ml⁻¹). The mechanisms involved in K562 cell death were investigated by confocal fluorescence microscopy, flow cytometry and immunoblot. Results CvL inhibited the growth of human leukemia cells, with IC₅₀ values of 70 and 100 μg ml⁻¹ for K562 and JURKAT cells, respectively, but it was ineffective on blood lymphocytes and solid tumor cell lines. K562 cell death occurred 72 h after exposure to the lectin and with signs of apoptosis, as analyzed by DAPI and annexin V/PI staining. Investigation of the possible mediators of this process showed that cell death occurred via a caspase-independent pathway. Confocal fluorescence microscopy indicated a pivotal role for the lysosomal protease cathepsin B in mediating cell death. Accordingly, pre-incubation of K562 cells with the cathepsin inhibitor l-trans-epoxysuccinyl-l-leucylamido-(4-guanidino)butane (E-64) abolished CvL cytotoxic effect. Furthermore, we found upregulation of tumor necrosis factor receptor 1 (TNFR1) and down-modulation of p65 subunit of nuclear factor kappa B (NFκB) expression in CvL-treated cells. These effects were accompanied by increased levels of p21 and reduced expression of pRb, suggesting that CvL can induce cell cycle arrest. Conclusions Collectively, these findings indicate an antileukemic effect for CvL and suggest that cathepsin B acts as a death mediator in CvL-induced cytotoxicity possibly in an uncharacterized connection with the membrane death receptor pathway.</description><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - isolation & purification</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis - drug effects</subject><subject>Biological and medical sciences</subject><subject>Cancer Research</subject><subject>Caspases - metabolism</subject><subject>Cell Culture Techniques</subject><subject>Cell Proliferation - drug effects</subject><subject>Cell Survival - drug effects</subject><subject>Cliona</subject><subject>Clione - chemistry</subject><subject>Flow Cytometry</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Immunoblotting</subject><subject>Inhibitory Concentration 50</subject><subject>Jurkat Cells</subject><subject>K562 Cells</subject><subject>Lectins - isolation & purification</subject><subject>Lectins - pharmacology</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphocytes - cytology</subject><subject>Lymphocytes - drug effects</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacology/Toxicology</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kU9v1DAQxS0EokvhA3ABCwluKTO28-9YraAgKvVQerYmWXvXJbGLnSzab1-vsqISB06WPb83bzyPsbcIFwhQf04AooECoCmgEWWhnrEVKinyTcnnbAVSqaKsQZ2xVyndA4BCKV-yM2zqBiWIFXNXMfyZdtz5nevcFOKBUz-5vZsOPFhO3Ie9Gfhg8qPnNoaRrwcXPPE9RUc-cdqS82niP8pK8N08kucmHqZdDIOZf5nREe_NMKTX7IWlIZk3p_Oc3X398nP9rbi-ufq-vrwu-rKSU1EqU4teNB1WIExLqoeqUhaNxfzn1log1XS2JqxrzNDGbERJLbSqbEVHG3nOPi19H2L4PZs06dGl4wTkTZiTFlABqlJk8MM_4H2Yo8-zaYFSNTIvKUO4QH0MKUVj9UN0I8WDRtDHEPQSgs4h6GMIWmXNu1PjuRvN5klx2noGPp4ASj0NNpLvXfrLZXesRF1nTixcyiW_NfFpwv-5v19EloKmbcyN724FZGOs8Lgk-QiGNKdu</recordid><startdate>20090501</startdate><enddate>20090501</enddate><creator>Queiroz, Alexandre F. S</creator><creator>Silva, Rodrigo A</creator><creator>Moura, Raniere M</creator><creator>Dreyfuss, Juliana L</creator><creator>Paredes-Gamero, Edgar J</creator><creator>Souza, Ana C. S</creator><creator>Tersariol, Ivarne L. S</creator><creator>Santos, Elizeu A</creator><creator>Nader, Helena B</creator><creator>Justo, Giselle Z</creator><creator>de Sales, Maurício P</creator><general>Berlin/Heidelberg : Springer-Verlag</general><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>8FD</scope><scope>F1W</scope><scope>FR3</scope><scope>H99</scope><scope>L.F</scope><scope>L.G</scope><scope>P64</scope></search><sort><creationdate>20090501</creationdate><title>Growth inhibitory activity of a novel lectin from Cliona varians against K562 human erythroleukemia cells</title><author>Queiroz, Alexandre F. S ; Silva, Rodrigo A ; Moura, Raniere M ; Dreyfuss, Juliana L ; Paredes-Gamero, Edgar J ; Souza, Ana C. S ; Tersariol, Ivarne L. S ; Santos, Elizeu A ; Nader, Helena B ; Justo, Giselle Z ; de Sales, Maurício P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c563t-54e72c28b1602e9a4c0664f1ef11009ff0a48bf7a1771b16ded25a9094592bad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - isolation & purification</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis - drug effects</topic><topic>Biological and medical sciences</topic><topic>Cancer Research</topic><topic>Caspases - metabolism</topic><topic>Cell Culture Techniques</topic><topic>Cell Proliferation - drug effects</topic><topic>Cell Survival - drug effects</topic><topic>Cliona</topic><topic>Clione - chemistry</topic><topic>Flow Cytometry</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Immunoblotting</topic><topic>Inhibitory Concentration 50</topic><topic>Jurkat Cells</topic><topic>K562 Cells</topic><topic>Lectins - isolation & purification</topic><topic>Lectins - pharmacology</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphocytes - cytology</topic><topic>Lymphocytes - drug effects</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacology/Toxicology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Queiroz, Alexandre F. S</creatorcontrib><creatorcontrib>Silva, Rodrigo A</creatorcontrib><creatorcontrib>Moura, Raniere M</creatorcontrib><creatorcontrib>Dreyfuss, Juliana L</creatorcontrib><creatorcontrib>Paredes-Gamero, Edgar J</creatorcontrib><creatorcontrib>Souza, Ana C. S</creatorcontrib><creatorcontrib>Tersariol, Ivarne L. S</creatorcontrib><creatorcontrib>Santos, Elizeu A</creatorcontrib><creatorcontrib>Nader, Helena B</creatorcontrib><creatorcontrib>Justo, Giselle Z</creatorcontrib><creatorcontrib>de Sales, Maurício P</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Technology Research Database</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Engineering Research Database</collection><collection>ASFA: Marine Biotechnology Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Marine Biotechnology Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Queiroz, Alexandre F. S</au><au>Silva, Rodrigo A</au><au>Moura, Raniere M</au><au>Dreyfuss, Juliana L</au><au>Paredes-Gamero, Edgar J</au><au>Souza, Ana C. S</au><au>Tersariol, Ivarne L. S</au><au>Santos, Elizeu A</au><au>Nader, Helena B</au><au>Justo, Giselle Z</au><au>de Sales, Maurício P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Growth inhibitory activity of a novel lectin from Cliona varians against K562 human erythroleukemia cells</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><stitle>Cancer Chemother Pharmacol</stitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2009-05-01</date><risdate>2009</risdate><volume>63</volume><issue>6</issue><spage>1023</spage><epage>1033</epage><pages>1023-1033</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>Purpose In this study, the antitumoral potential of a novel lectin (CvL) purified from the marine sponge Cliona varians was studied in different cancer cell lines. Methods CvL cytotoxicity was evaluated in mammalian tumor cells and in normal human peripheral blood lymphocytes by the MTT assay using the same range of concentrations (1-150 μg ml⁻¹). The mechanisms involved in K562 cell death were investigated by confocal fluorescence microscopy, flow cytometry and immunoblot. Results CvL inhibited the growth of human leukemia cells, with IC₅₀ values of 70 and 100 μg ml⁻¹ for K562 and JURKAT cells, respectively, but it was ineffective on blood lymphocytes and solid tumor cell lines. K562 cell death occurred 72 h after exposure to the lectin and with signs of apoptosis, as analyzed by DAPI and annexin V/PI staining. Investigation of the possible mediators of this process showed that cell death occurred via a caspase-independent pathway. Confocal fluorescence microscopy indicated a pivotal role for the lysosomal protease cathepsin B in mediating cell death. Accordingly, pre-incubation of K562 cells with the cathepsin inhibitor l-trans-epoxysuccinyl-l-leucylamido-(4-guanidino)butane (E-64) abolished CvL cytotoxic effect. Furthermore, we found upregulation of tumor necrosis factor receptor 1 (TNFR1) and down-modulation of p65 subunit of nuclear factor kappa B (NFκB) expression in CvL-treated cells. These effects were accompanied by increased levels of p21 and reduced expression of pRb, suggesting that CvL can induce cell cycle arrest. Conclusions Collectively, these findings indicate an antileukemic effect for CvL and suggest that cathepsin B acts as a death mediator in CvL-induced cytotoxicity possibly in an uncharacterized connection with the membrane death receptor pathway.</abstract><cop>Berlin/Heidelberg</cop><pub>Berlin/Heidelberg : Springer-Verlag</pub><pmid>18781302</pmid><doi>10.1007/s00280-008-0825-4</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0344-5704 |
ispartof | Cancer chemotherapy and pharmacology, 2009-05, Vol.63 (6), p.1023-1033 |
issn | 0344-5704 1432-0843 |
language | eng |
recordid | cdi_proquest_miscellaneous_20601452 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Animals Antineoplastic agents Antineoplastic Agents - isolation & purification Antineoplastic Agents - pharmacology Apoptosis - drug effects Biological and medical sciences Cancer Research Caspases - metabolism Cell Culture Techniques Cell Proliferation - drug effects Cell Survival - drug effects Cliona Clione - chemistry Flow Cytometry Hematologic and hematopoietic diseases Humans Immunoblotting Inhibitory Concentration 50 Jurkat Cells K562 Cells Lectins - isolation & purification Lectins - pharmacology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphocytes - cytology Lymphocytes - drug effects Medical sciences Medicine Medicine & Public Health Oncology Original Article Pharmacology. Drug treatments Pharmacology/Toxicology |
title | Growth inhibitory activity of a novel lectin from Cliona varians against K562 human erythroleukemia cells |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T17%3A26%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Growth%20inhibitory%20activity%20of%20a%20novel%20lectin%20from%20Cliona%20varians%20against%20K562%20human%20erythroleukemia%20cells&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Queiroz,%20Alexandre%20F.%20S&rft.date=2009-05-01&rft.volume=63&rft.issue=6&rft.spage=1023&rft.epage=1033&rft.pages=1023-1033&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/s00280-008-0825-4&rft_dat=%3Cproquest_cross%3E20601452%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213483878&rft_id=info:pmid/18781302&rfr_iscdi=true |